Barinthus Biotherapeutics (BRNS) AI Stock Analysis

• Market Cap: $56.48M
• Dividend Yield: N/A
• Average Volume (3M): 2.57M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.73
• Revenue Growth: 4413.19%
• EPS Growth: 10.56%
• Country: US
• Employees: 105
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): -0.49
• Shares Outstanding: 40,339,394
• 10 Day Avg. Volume: 469,747
• 30 Day Avg. Volume: 2,566,043
• PEG Ratio: 0.16
• Price to Book (P/B): 0.54
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.43
• Enterprise Value/Market Cap: -0.44
• Enterprise Value/Revenue: -11.49
• Enterprise Value/Gross Profit: -69.84
• Enterprise Value/Ebitda: 0.23
• 1Y Price Target: $3.00
• Price Target Upside: 114.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 56 Neutral
• Price Target: $2.00 ▲(42.86%Upside)

The overall score is driven by technical analysis indicating positive momentum, despite financial challenges and a poor valuation. The company's financial performance is a significant risk, but the stock's current trend provides some optimism.

Positive Factors

Analyst Recommendation

Analyst reiterates a Buy rating and sets a $3 price target on the stock.

Clinical Trials

Positive results from VTP-300 Phase 2 trials in chronic hepatitis B show potential for achieving a functional cure.

Financial Resources

With $100.6M in cash, management expects to have enough capital to fund operations into 2027.

Negative Factors

Clinical Risks

Risks include potential failure of therapeutic candidates in clinical trials and failure to secure regulatory approval.

Financial Performance

Net losses exceeded expectations, with a reported loss of $19.6M compared to the estimated $12.0M.

Impairment Expense

The company faced a $12.2M goodwill impairment expense, impacting financial performance.

Barinthus Biotherapeutics Business Overview & Revenue Model

Company Description

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

How the Company Makes Money

Barinthus Biotherapeutics generates revenue through a multifaceted business model that includes product sales, licensing agreements, and strategic partnerships. The company earns income from the commercialization of its proprietary therapies, which are sold to healthcare providers and institutions. Additionally, Barinthus licenses its technologies and drug candidates to other pharmaceutical companies, earning royalty payments and milestone fees. The company also engages in collaborative research and development partnerships, which provide funding and shared revenue opportunities. These collaborations often include co-development and co-marketing agreements that further enhance Barinthus's financial position.

Barinthus Biotherapeutics Financial Statement Overview

Summary

Barinthus Biotherapeutics faces significant financial challenges with ongoing losses and negative cash flows, despite improvements in revenue and gross profit margins. The balance sheet is stable but needs focus on profitability and cash flow improvement.

Income Statement

Barinthus Biotherapeutics has shown significant volatility in its revenue and profitability. The revenue growth from 2023 to 2024 was substantial, but the company remains unprofitable with negative net income and EBIT margins. The gross profit margin improved in 2024, indicating better cost management, but the overall financial health is hindered by persistent losses.

Balance Sheet

The company's balance sheet reflects a strong equity position with a high equity ratio, indicating stability. However, the debt-to-equity ratio is relatively low, suggesting manageable leverage. The decline in stockholders' equity over the years is a concern, but the reduction in total liabilities is a positive sign.

Cash Flow

Cash flow analysis reveals challenges with negative operating and free cash flows, indicating potential liquidity issues. The free cash flow has improved slightly from 2023 to 2024, but the company continues to burn cash, which could be a risk if not addressed.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.97M	802.00K	44.70M	268.00K	4.82M
Gross Profit	9.17M	-4.64M	44.70M	268.00K	4.82M
EBITDA	-55.37M	-71.06M	6.40M	-47.87M	-14.03M
Net Income	-61.07M	-73.35M	5.34M	-50.87M	-17.71M
Balance Sheet
Total Assets	160.33M	214.51M	270.20M	280.71M	50.67M
Cash, Cash Equivalents and Short-Term Investments	110.66M	142.09M	194.38M	214.05M	43.27M
Total Debt	12.01M	12.98M	8.77M	7.22M	46.36M
Total Liabilities	30.19M	27.51M	27.00M	28.15M	87.58M
Stockholders Equity	130.03M	186.78M	242.90M	252.13M	-37.30M
Cash Flow
Free Cash Flow	-29.83M	-56.34M	-20.57M	-33.73M	-11.32M
Operating Cash Flow	-28.94M	-50.92M	-14.43M	-32.58M	-11.03M
Investing Cash Flow	-892.00K	-5.41M	-5.75M	-12.91M	-293.00K
Financing Cash Flow	2.16M	1.87M	325.00K	222.74M	41.44M

Barinthus Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRNS, the sentiment is Positive. The current price of 1.4 is below the 20-day moving average (MA) of 1.41, above the 50-day MA of 1.12, and above the 200-day MA of 1.05, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 51.81 is Neutral, neither overbought nor oversold. The STOCH value of 10.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BRNS.

Barinthus Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BRNS	56 Neutral	$56.48M	―	-45.40%	―	4413.19%	10.56%
Sector *	51 Neutral	$7.35B	0.50	-65.61%	2.47%	15.28%	1.44%
ALGS	51 Neutral	$45.62M	―	-60.44%	―	-76.29%	―
CLGN	45 Neutral	$29.13M	―	-75.27%	―	-76.73%	-85.83%
GDTC	41 Neutral	$22.97M	―	-24.97%	―	―	38.80%
BOLD	40 Underperform	$25.97M	―	-54.06%	―	―	―
ALXO	39 Underperform	$30.33M	―	-102.99%	―	―	30.37%

Barinthus Biotherapeutics Corporate Events

Barinthus Biotherapeutics Approves Key Proposals at AGM

On June 10, 2025, Barinthus Biotherapeutics held its Annual General Meeting where all proposed matters were approved, including the re-election of directors and the appointment of auditors. The meeting also covered financial matters such as the approval of the directors’ remuneration policy and the decision not to pay dividends for the fiscal year ending December 31, 2024.

The most recent analyst rating on (BRNS) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Barinthus Biotherapeutics stock, see the BRNS Stock Forecast page.

Barinthus Biotherapeutics Restructures Leadership with New CFO

Barinthus Biotherapeutics announced significant corporate developments, including the termination of Gemma Brown as CFO as part of a restructuring plan, with William Enright assuming her financial responsibilities. The company presented promising data from its HBV003 and IM-PROVE II trials at the EASL Congress, highlighting the potential of VTP-300 in combination with other treatments for chronic hepatitis B. These developments are part of Barinthus Bio’s strategic focus on immunological and inflammatory diseases, aiming to strengthen its market positioning and support ongoing partnering efforts.